Clinical Trial Update: Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab and/or ipilimumab with or without azacitidine for myelodysplastic syndromes; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING